Ozempic Increase Is An Opportunity For Health Insurers

The progress is basically because of continued utilization of drugs and higher prices for specialty medicine but will be partially offset by reimbursement stress, lowered profit margins, and the expansion of specialty generics and biosimilars. In July 2022, we estimated that 2022 HST profit pools can be $53.7 billion. We have revised our estimate to […]

Ozempic Increase Is An Opportunity For Health Insurers Read More »